Company profile: Alethia Biotherapeutics
1.1 - Company Overview
Company description
- Provider of monoclonal antibody-based therapeutics for cancer-associated diseases, including AB-16B5, a humanized IgG2 antibody targeting secreted clusterin to inhibit EMT, enhance chemotherapy response, and reduce tumor invasion; AB-3A4, developed as an ADC targeting KAAG1 for ovarian and triple-negative breast cancers; and STAR technology for discovering differentially expressed mRNA sequences, including rare ones, to identify novel therapeutic targets.
Products and services
- AB-16B5: A humanized IgG2 monoclonal antibody targeting secreted clusterin to suppress epithelial-to-mesenchymal transition, thereby enhancing chemotherapy responsiveness and reducing tumor invasion across cancers
- AB-3A4: A high-affinity antibody engineered as an antibody-drug conjugate (ADC) that targets the KAAG1 antigen to treat ovarian and triple-negative breast cancers
- Subtractive Transcription-based Amplification of mRNA (STAR): A proprietary discovery platform identifying differentially expressed mRNA sequences, including rare transcripts, to pinpoint novel therapeutic targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alethia Biotherapeutics
EMcision
HQ: United Kingdom
Website
- Description: Provider of medical devices for gastrointestinal applications, offering the Habib EndoHPB, an endoscopic bipolar RF probe developed to ablate tissue in the gastro-intestinal tract, and the Habib Endoblate, a bipolar RF probe for endoluminal ablation of gastrointestinal tumours.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMcision company profile →
Eikonoklastes
HQ: United States
Website
- Description: Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eikonoklastes company profile →
Cero Therapeutics
HQ: United States
Website
- Description: Provider of cellular immunotherapy centered on a CER T-cell platform that integrates anti-tumor capabilities of the innate and adaptive immune systems into a single T cell, aimed at treating hematologic malignancies and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cero Therapeutics company profile →
Forty Seven
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology therapies targeting cancer immune evasion pathways, based on technology licensed from Stanford University. Lead program 5F9 is a monoclonal antibody against the CD47 receptor, a 'don't eat me' signal that cancer cells commandeer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forty Seven company profile →
NuView Life Sciences
HQ: United States
Website
- Description: Provider of medical imaging and diagnostic solutions leveraging the NV-VPAC1 peptide to target VPAC1 receptors for PET imaging and theranostic applications. Offers in vitro urine-based diagnostic kits for detecting prostate and bladder cancer, in vivo PET agents for diagnosing breast and prostate cancer, and peptide-guided delivery of isotopes (e.g., Copper-64 for imaging, Copper-67 for treatment).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuView Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alethia Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alethia Biotherapeutics
2.2 - Growth funds investing in similar companies to Alethia Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alethia Biotherapeutics
4.2 - Public trading comparable groups for Alethia Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →